Opioid receptor could guide drug R&D on addiction

Investigators from the Florida campus of the Scripps Research Institute have found that a compound that favors a certain biological pathway could provide scientists with a roadmap for future development of more effective drugs for addiction. In both cell and animal studies, researchers discovered that the compound, known as 6'-guanidinonaltrindole (6'-GNTI), has a strong disposition toward a single biological pathway--the kappa opioid receptor. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.